GB0715216D0 - Leptin - Google Patents

Leptin

Info

Publication number
GB0715216D0
GB0715216D0 GBGB0715216.8A GB0715216A GB0715216D0 GB 0715216 D0 GB0715216 D0 GB 0715216D0 GB 0715216 A GB0715216 A GB 0715216A GB 0715216 D0 GB0715216 D0 GB 0715216D0
Authority
GB
United Kingdom
Prior art keywords
leptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0715216.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asterion Ltd
Original Assignee
Asterion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Ltd filed Critical Asterion Ltd
Priority to GBGB0715216.8A priority Critical patent/GB0715216D0/en
Publication of GB0715216D0 publication Critical patent/GB0715216D0/en
Priority to PCT/GB2008/002489 priority patent/WO2009019427A1/en
Priority to US12/671,979 priority patent/US20110092417A1/en
Priority to CN200880110351A priority patent/CN101827858A/zh
Priority to EP08776011A priority patent/EP2185585A1/en
Priority to JP2010519503A priority patent/JP2010535486A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
GBGB0715216.8A 2007-08-03 2007-08-03 Leptin Ceased GB0715216D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0715216.8A GB0715216D0 (en) 2007-08-03 2007-08-03 Leptin
PCT/GB2008/002489 WO2009019427A1 (en) 2007-08-03 2008-07-23 Leptin fusion proteins
US12/671,979 US20110092417A1 (en) 2007-08-03 2008-07-23 Leptin fusion proteins
CN200880110351A CN101827858A (zh) 2007-08-03 2008-07-23 瘦蛋白融合蛋白
EP08776011A EP2185585A1 (en) 2007-08-03 2008-07-23 Leptin fusion proteins
JP2010519503A JP2010535486A (ja) 2007-08-03 2008-07-23 レプチン融合タンパク質

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0715216.8A GB0715216D0 (en) 2007-08-03 2007-08-03 Leptin

Publications (1)

Publication Number Publication Date
GB0715216D0 true GB0715216D0 (en) 2007-09-12

Family

ID=38529304

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0715216.8A Ceased GB0715216D0 (en) 2007-08-03 2007-08-03 Leptin

Country Status (6)

Country Link
US (1) US20110092417A1 (https=)
EP (1) EP2185585A1 (https=)
JP (1) JP2010535486A (https=)
CN (1) CN101827858A (https=)
GB (1) GB0715216D0 (https=)
WO (1) WO2009019427A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
ES2732475T3 (es) * 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US10550192B2 (en) 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
WO2019126071A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
DK3773713T3 (da) 2018-04-06 2025-08-18 Regeneron Pharma Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI
CN109942716B (zh) * 2019-04-08 2023-05-12 河南师范大学 一种用于治疗代谢疾病的瘦素融合蛋白及其制备方法和应用
CN111848774B (zh) * 2020-08-05 2022-05-10 武汉海特生物制药股份有限公司 一种美曲普汀的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
JP4660062B2 (ja) * 2000-06-16 2011-03-30 アステリオン・リミテッド 結合剤
EP1771467A2 (en) * 2004-07-26 2007-04-11 Asterion Limited Linkers
WO2007080404A2 (en) * 2006-01-12 2007-07-19 Asterion Limited Leptin ligand

Also Published As

Publication number Publication date
JP2010535486A (ja) 2010-11-25
EP2185585A1 (en) 2010-05-19
US20110092417A1 (en) 2011-04-21
WO2009019427A1 (en) 2009-02-12
CN101827858A (zh) 2010-09-08

Similar Documents

Publication Publication Date Title
ZA201002568B (en) Herbicide-safener combination
GB0706633D0 (en) Combination
DE602008005470D1 (en) Imidazopyridinone
GB0702456D0 (en) New combination
GB0725299D0 (en) Portaboard
GB0702385D0 (en) New combination
GB0715216D0 (en) Leptin
GB0702416D0 (en) New combination
ZA201002562B (en) Combination thepary
GB0716271D0 (en) SafekeyP
GB0709749D0 (en) Juglr
GB0716009D0 (en) Mobcap
GB0714804D0 (en) Level-bed
GB0714357D0 (en) Aminobenzotriazoles
GB0705849D0 (en) Jellyloss
AU3646P (en) TAS300 Dianella tasmanica
HU0700365D0 (en) Combination
GB0707145D0 (en) Combination therapy - 793
GB0703405D0 (en) Eco-hat
GB0721473D0 (en) Magnatie
GB0707032D0 (en) Abctens
AU2007247V (en) CalredGL Calothamnus quadrifidus
GB0703796D0 (en) Espressotiere
GB0705715D0 (en) Maglift
AU320545S (en) Multi-opener

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)